Ropes, Wilson Sonsini Guide Gilead's $7.8B Arcellx Buy

By Al Barbarino · February 23, 2026, 1:36 PM EST

Gilead Sciences Inc. announced Monday that it has agreed to acquire clinical-stage biotechnology company Arcellx Inc. for $115 per share in cash plus one contingent value right worth $5 per share,...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login